11/20/15, Research and Development Bayer’s new five-year-contraceptive submitted for EU and US Marketing Authorization Clinical studies demonstrated efficacy of new long-acting contraceptive with lowest available daily hormone dose for five years of contraception more
11/06/15, Research and Development Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA SOCRATES-REDUCED Phase IIb study results of vericiguat in patients with worsening chronic heart failure and reduced ejection fraction (HFrEF) more
|Research expenses 2014||EUR 1,878 million|
|In percent of division sales 2014
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.